semaglutides approved for weight loss FDA approves obesity drug that helped people cut 15% GLP-1 Weight Loss Options |
Description
This is similar to an Ozempic Class Action Lawsuit
The LEADER and SUSTAIN trials showed that semaglutide reduced major adverse cardiac events by 26% in people with type 2 diabetes and existing cardiovascular disease
Whats happening
It is also licensed for weight management in adolescents aged 12 years and above with obesity
The symptoms of blood clots can include swelling, pain, redness, and warmth in the affected area for DVT, and shortness of breath, chest pain, and coughing up blood for PE
